Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models.
暂无分享,去创建一个
Claus-Michael Lehr | Nicole Schneider-Daum | C. Lehr | Marius Hittinger | N. Schneider-Daum | Cristiane de Souza Carvalho | J. Juntke | S. Kletting | Marius Hittinger | Jenny Juntke | Stephanie Kletting | Cristiane de Souza Carvalho | M. Hittinger | Stephanie Kletting
[1] Driton Vllasaliu,et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. , 2010, International journal of pharmaceutics.
[2] U. Gupta,et al. Animal Models of Tuberculosis , 2005, Tuberculosis.
[3] Giuseppe Rodi,et al. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report , 2007, Orphanet journal of rare diseases.
[4] Ping Li,et al. Autophagy mediates avian influenza H5N1 pseudotyped particle-induced lung inflammation through NF-κB and p38 MAPK signaling pathways. , 2014, American journal of physiology. Lung cellular and molecular physiology.
[5] P. Byron,et al. Tobramycin Disposition in the Rat Lung Following Airway Administration , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[6] F. Ahsan,et al. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. , 2004, Journal of pharmaceutical sciences.
[7] Claus-Michael Lehr,et al. The cell line NCl-H441 is a useful in vitro model for transport studies of human distal lung epithelial barrier. , 2014, Molecular pharmaceutics.
[8] A. Hickey,et al. The guinea pig as a model of infectious diseases. , 2008, Comparative medicine.
[9] D. Hansell,et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis , 2000, Thorax.
[10] Christian Mühlfeld,et al. Particle and Fibre Toxicology Translocation of Particles and Inflammatory Responses after Exposure to Fine Particles and Nanoparticles in an Epithelial Airway Model , 2022 .
[11] T. Umino,et al. TGF-β and glutathione promote tissue repair in cigarette smoke induced injury. , 2007 .
[12] M. Virji,et al. Involvement of the autophagy pathway in trafficking of Mycobacterium tuberculosis bacilli through cultured human type II epithelial cells , 2012, Cellular microbiology.
[13] S. Johnston,et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.
[14] A. Amirfazli,et al. Factors affecting magnetic retention of particles in the upper airways: an in vitro and ex vivo study. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[15] Qiang Zhang,et al. Transport of proteins and peptides across human cultured alveolar A549 cell monolayer. , 2004, International journal of pharmaceutics.
[16] M. Niederman,et al. Community-Acquired Pneumonia: An Unfinished Battle , 2011, Medical Clinics of North America.
[17] A. Gutleb,et al. Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[18] J. Cassiman,et al. Established cell lines used in cystic fibrosis research. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[19] E. Schwiebert,et al. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] D. Baines,et al. Forskolin-induced Cell Shrinkage and Apical Translocation of Functional Enhanced Green Fluorescent Protein-Human αENaC in H441 Lung Epithelial Cell Monolayers* , 2006, Journal of Biological Chemistry.
[21] Jeffrey R. Galvin,et al. From the archives of the AFIP: pulmonary alveolar proteinosis. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.
[22] A. Goolaerts,et al. Differentiation of Epithelial Na+ Channel Function , 2005, Journal of Biological Chemistry.
[23] C. Harris,et al. Sv40‐induced immortalization and ras‐transformation of human bronchial epithelial cells , 1995, International journal of cancer.
[24] Karen A Robinson,et al. Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .
[25] W. Koch,et al. Functional Testing of an Inhalable Nanoparticle Based Influenza Vaccine Using a Human Precision Cut Lung Slice Technique , 2013, PloS one.
[26] T S Nawrot,et al. Co-cultures of multiple cell types mimic pulmonary cell communication in response to urban PM10 , 2008, European Respiratory Journal.
[27] J. Wine. The Development of Lung Disease in Cystic Fibrosis Pigs , 2010, Science Translational Medicine.
[28] B. Ruggeri,et al. Animal models of human disease: challenges in enabling translation. , 2014, Biochemical pharmacology.
[29] K. Audus,et al. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. , 1998, Experimental cell research.
[30] Carsten Kneuer,et al. Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o–: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies , 2002, Cell and Tissue Research.
[31] Robert L. Hunter,et al. A Humanized Mouse Model of Tuberculosis , 2013, PloS one.
[32] S. Shoyele,et al. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. , 2006, International journal of pharmaceutics.
[33] O. Bajolet,et al. Airway mucus in cystic fibrosis. , 2002, Paediatric respiratory reviews.
[34] Ben Forbes,et al. Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier , 2006, Pharmaceutical Research.
[35] Yuanyuan Xiao,et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. , 2007, The Journal of clinical investigation.
[36] B. Stanton,et al. Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. , 2010, Journal of visualized experiments : JoVE.
[37] M. Camatini,et al. The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells. , 2013, Toxicology letters.
[38] A. Hickey,et al. Inhaled Drug Delivery for Tuberculosis Therapy , 2009, Pharmaceutical Research.
[39] M. Gumbleton,et al. The particle has landed--characterizing the fate of inhaled pharmaceuticals. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[40] C. Turkington,et al. The Encyclopedia of Infectious Diseases , 1998 .
[41] M. Bebawy,et al. Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model , 2013, Antimicrobial Agents and Chemotherapy.
[42] S. Bozinovski,et al. Recent advances in pre-clinical mouse models of COPD , 2013, Clinical science.
[43] P. Lackie,et al. Interactions between endothelial cells and epithelial cells in a combined cell model of airway mucosa: effects on tight junction permeability , 2010, Experimental lung research.
[44] Ben Forbes,et al. Human respiratory epithelial cell culture for drug delivery applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[45] Y. Korchev,et al. Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. , 2008, American journal of respiratory cell and molecular biology.
[46] S. Diggle,et al. Development of an Ex Vivo Porcine Lung Model for Studying Growth, Virulence, and Signaling of Pseudomonas aeruginosa , 2014, Infection and Immunity.
[47] H. Yonezawa,et al. Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae , 2014, BMC Microbiology.
[48] B. Grant,et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[49] P. Paré,et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[50] Martin Mohr,et al. Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways , 2010, Journal of The Royal Society Interface.
[51] Wei Gao,et al. Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-β1 in a coculture system , 2010, Clinical and Experimental Medicine.
[52] Kevin Kendall,et al. Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles , 2013, Nanotoxicology.
[53] Kathleen J. Menard. Whole lung lavage in the treatment of pulmonary alveolar proteinosis. , 2005, Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses.
[54] K. Juni,et al. Permeability of Peptides and Proteins in Human Cultured Alveolar A549 Cell Monolayer , 1995, Pharmaceutical Research.
[55] S. H. Rosen,et al. Pulmonary alveolar proteinosis. , 1958, The New England journal of medicine.
[56] R. Ryan,et al. Modelling Co-Infection of the Cystic Fibrosis Lung by Pseudomonas aeruginosa and Burkholderia cenocepacia Reveals Influences on Biofilm Formation and Host Response , 2012, PloS one.
[57] G. O’Toole,et al. In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells , 2008, Infection and Immunity.
[58] I. Kilty,et al. The role of IFN-γ in regulation of IFN-γ-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures , 2007, Respiratory research.
[59] U. Römling,et al. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. , 2005, Journal of medical microbiology.
[60] Robert Landsiedel,et al. In vivo-in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[61] A. Harnden,et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011 , 2011, Thorax.
[62] M. Gumbleton,et al. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers , 2007, Cell and Tissue Research.
[63] B. Penke,et al. In Vitro and in Vivo Nuclear Factor-κB Inhibitory Effects of the Cell-Penetrating Penetratin Peptide , 2006, Molecular Pharmacology.
[64] Daniel J Klionsky,et al. Development by self-digestion: molecular mechanisms and biological functions of autophagy. , 2004, Developmental cell.
[65] A. Winkelmann,et al. The Clara cell: a “Third Reich eponym”? , 2010, European Respiratory Journal.
[66] W. Kummer,et al. Barrier functions and paracellular integrity in human cell culture models of the proximal respiratory unit. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[67] W. Craig,et al. Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.
[68] C. Lehr,et al. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. , 2013, The Lancet. Respiratory medicine.
[69] J. Schwartzman,et al. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. , 2012, The Journal of antimicrobial chemotherapy.
[70] C. Ehrhardt,et al. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. , 2013, Therapeutic delivery.
[71] B. Rothen‐Rutishauser,et al. Macrophages and dendritic cells express tight junction proteins and exchange particles in an in vitro model of the human airway wall. , 2011, Immunobiology.
[72] Armin Braun,et al. Assessment of immunotoxicity using precision-cut tissue slices , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[73] S. Chan,et al. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. , 2013, International journal of pharmaceutics.
[74] H. McShane,et al. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data☆ , 2014, Tuberculosis.
[75] E. Swiatlo,et al. Deletion of arcD in Streptococcus pneumoniae D39 Impairs Its Capsule and Attenuates Virulence , 2013, Infection and Immunity.
[76] S. Mcphee,et al. Pathophysiology of Disease: An Introduction to Clinical Medicine , 1995 .
[77] Daniel C Leslie,et al. A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.
[78] Karen A Robinson,et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.
[79] N. Høiby. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis , 2011, BMC medicine.
[80] Mattias Svensson,et al. Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue , 2013, Disease Models & Mechanisms.
[81] C. Ehrhardt,et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o- , 2006, Cell and Tissue Research.
[82] Bruce A. Stanton,et al. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. , 2008, Pulmonary pharmacology & therapeutics.
[83] Kirsten Peters,et al. Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo-capillary barrier in vitro , 2004, Laboratory Investigation.
[84] Christine Pohl,et al. Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures , 2011, Particle and Fibre Toxicology.
[85] E. Marchiori,et al. Comparative study of clinical, pathological and HRCT findings of primary alveolar proteinosis and silicoproteinosis. , 2012, European journal of radiology.
[86] L. Ramakrishnan. Revisiting the role of the granuloma in tuberculosis , 2012, Nature Reviews Immunology.
[87] Claus-Michael Lehr,et al. Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. , 2014, Advanced drug delivery reviews.
[88] Jennifer M. Smith,et al. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. , 2005, Biomaterials.
[89] S. Richter,et al. Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth , 2010, Science Translational Medicine.
[90] J. Elborn,et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[91] Bin Chen,et al. Immunization against Multidrug-Resistant Acinetobacter baumannii Effectively Protects Mice in both Pneumonia and Sepsis Models , 2014, PloS one.
[92] A. Cuervo. Autophagy: in sickness and in health. , 2004, Trends in cell biology.
[93] Rachael M. Crist,et al. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity , 2012, Particle and Fibre Toxicology.
[94] K. Roemer,et al. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C , 2002, Cell and Tissue Research.
[95] D. Ingber,et al. Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.
[96] B. Meibohm,et al. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. , 2010, Future medicinal chemistry.
[97] M. Pallardy,et al. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. , 2013, International journal of pharmaceutics.
[98] R. Pandey,et al. Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.
[99] Claus-Michael Lehr,et al. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[100] J. Juarez,et al. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria , 2013, Proceedings of the National Academy of Sciences.
[101] P. Dubruel,et al. An impaired alveolar-capillary barrier in vitro: effect of proinflammatory cytokines and consequences on nanocarrier interaction , 2010, Journal of The Royal Society Interface.
[102] S. Ranganathan,et al. Pneumonia and Other Respiratory Infections , 2009, Pediatric Clinics of North America.
[103] R. Pandey,et al. Nanomedicine and experimental tuberculosis: facts, flaws, and future. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[104] R. Barrios. Animal Models of Lung Disease , 2009 .
[105] B. Maycher,et al. Radiological imaging in pneumonia: recent innovations , 2007, Current opinion in pulmonary medicine.
[106] S. Molin,et al. Novel Mouse Model of Chronic Pseudomonas aeruginosa Lung Infection Mimicking Cystic Fibrosis , 2005, Infection and Immunity.
[107] C. Alexander,et al. Epithelial toxicity of alkylglycoside surfactants. , 2013, Journal of pharmaceutical sciences.
[108] Corona M. Cassidy,et al. Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot study. , 2011, Photodiagnosis and photodynamic therapy.
[109] N. A. Whitehead,et al. Quorum sensing as a population-density-dependent determinant of bacterial physiology. , 2001, Advances in microbial physiology.
[110] C. Deb,et al. Human Granuloma In Vitro Model, for TB Dormancy and Resuscitation , 2013, PloS one.
[111] C. Di Serio,et al. Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis Airways Influences Virulence of Staphylococcus aureus In Vitro and Murine Models of Co-Infection , 2014, PloS one.
[112] R. Devlin,et al. TLR-2 is involved in airway epithelial cell response to air pollution particles. , 2005, Toxicology and applied pharmacology.
[113] C. Bai,et al. Therapeutic role of terbutaline in a rat whole-lung lavage model , 2011, Experimental lung research.
[114] Z. Borok,et al. A Useful In Vitro Model for Transport Studies of Alveolar Epithelial Barrier , 2001, Pharmaceutical Research.
[115] José Vassallo,et al. Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs , 2013, PloS one.
[116] S. Anderson,et al. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. , 2013, Molecular pharmaceutics.
[117] D. Klee,et al. Influence of particle size and material properties on mucociliary clearance from the airways. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[118] M. Bates,et al. Human monocytic cells direct the robust release of CXCL10 by bronchial epithelial cells during rhinovirus infection , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[119] Jiyong Jing,et al. Pulmonary alveolar proteinosis in China: A systematic review of 241 cases , 2009, Respirology.
[120] Gerhard Scheuch,et al. Clinical perspectives on pulmonary systemic and macromolecular delivery. , 2006, Advanced drug delivery reviews.
[121] Jeffrey C. Pommerville,et al. Alcamo's Fundamentals of Microbiology , 2004 .
[122] A. Perkins,et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.
[123] Emily V. Chambers,et al. Mycoplasma pneumoniae host-pathogen studies in an air-liquid culture of differentiated human airway epithelial cells. , 2007, Microbial pathogenesis.
[124] C. Kirkpatrick,et al. Side-specific effects by cadmium exposure: apical and basolateral treatment in a coculture model of the blood-air barrier. , 2010, Toxicology and applied pharmacology.
[125] V. Haley,et al. Quantifying Sources of Bias in National Healthcare Safety Network Laboratory-Identified Clostridium difficile Infection Rates , 2014, Infection Control & Hospital Epidemiology.
[126] N. Ozaki,et al. Up-regulation of surfactant protein production in a mouse model of secondary pulmonary alveolar proteinosis. , 2009, American journal of respiratory cell and molecular biology.
[127] L. Saiman,et al. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update , 2014, Infection Control & Hospital Epidemiology.
[128] A. Dunn,et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[129] M. Karimi,et al. Features of idiopathic pulmonary alveolar proteinosis in high resolution computed tomography , 2014, Polish journal of radiology.
[130] Nilesh Patel,et al. Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[131] B. Forbes,et al. Inflammatory Response and Barrier Properties of a New Alveolar Type 1-Like Cell Line (TT1) , 2009, Pharmaceutical Research.
[132] M. Schluchter,et al. Murine models of chronic Pseudomonas aeruginosa lung infection , 2002, Laboratory animals.
[133] C. Lehr,et al. Isolation, cultivation, and application of human alveolar epithelial cells. , 2012, Methods in molecular biology.
[134] Min-Ki Lee,et al. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. , 2007, Journal of pharmaceutical sciences.
[135] M. Maciá,et al. Antimicrobial susceptibility testing in biofilm-growing bacteria. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[136] Forbes,et al. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. , 2000, Pharmaceutical science & technology today.
[137] C. Lehr,et al. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[138] C. Lehr,et al. Embryonic Chicken Trachea as a New In Vitro Model for the Investigation of Mucociliary Particle Clearance in the Airways , 2008, AAPS PharmSciTech.
[139] R. Vanbever,et al. Preclinical models for pulmonary drug delivery , 2009, Expert opinion on drug delivery.
[140] R. Hartmann,et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[141] S. Mitragotri,et al. Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge--an ex vivo and in silico approach. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[142] Roger L. White. What In Vitro Models of Infection Can and Cannot Do , 2001, Pharmacotherapy.
[143] S. Kirchner,et al. Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung , 2012, Journal of visualized experiments : JoVE.
[144] M. Cosio,et al. Inflammation of the airways and lung parenchyma in COPD: role of T cells. , 2002, Chest.
[145] T. Murphy,et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[146] Gerald B. Pier,et al. Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.
[147] J. Crapo,et al. Allometric relationships of cell numbers and size in the mammalian lung. , 1992, American journal of respiratory cell and molecular biology.
[148] M. Fliegauf,et al. Mucociliary Clearance Defects in a Murine In Vitro Model of Pneumococcal Airway Infection , 2013, PloS one.
[149] Valérie Zuang,et al. A Modular Approach to the ECVAM Principles on Test Validity , 2004, Alternatives to laboratory animals : ATLA.
[150] A. Meijer,et al. Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment. , 2014, ACS nano.
[151] D. Newman,et al. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. , 2012, American journal of respiratory cell and molecular biology.
[152] J. Colmer-Hamood,et al. Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium , 2012, BMC Microbiology.
[153] J. Bueno. Antitubercular In Vitro Drug Discovery: Tools for Begin the Search , 2012 .
[154] H. Junginger,et al. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[155] Song Huang,et al. In vitro organ culture models of asthma , 2009 .
[156] M. Cavet,et al. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells , 1997, Antimicrobial agents and chemotherapy.
[157] P. Paré,et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. , 2001, American journal of respiratory and critical care medicine.
[158] Christopher S. Stach,et al. Vaccination against Staphylococcus aureus pneumonia. , 2014, The Journal of infectious diseases.
[159] Arno C Gutleb,et al. An improved 3D tetraculture system mimicking the cellular organisation at the alveolar barrier to study the potential toxic effects of particles on the lung , 2013, Particle and Fibre Toxicology.
[160] M. Sakagami,et al. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. , 2006, Advanced drug delivery reviews.
[161] D. Steinemann,et al. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. , 2013, American journal of respiratory and critical care medicine.
[162] R. Hartmann,et al. Identification of small-molecule antagonists of the Pseudomonas aeruginosa transcriptional regulator PqsR: biophysically guided hit discovery and optimization. , 2012, ACS chemical biology.
[163] Jeremy L. Steinbacher,et al. Differences in gene expression and cytokine production by crystalline vs. amorphous silica in human lung epithelial cells , 2012, Particle and Fibre Toxicology.
[164] B. Rubin. Mucus structure and properties in cystic fibrosis. , 2007, Paediatric respiratory reviews.
[165] F. Tuya,et al. A Meta-Analysis of Seaweed Impacts on Seagrasses: Generalities and Knowledge Gaps , 2012, PloS one.
[166] Peter Gehr,et al. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. , 2005, American journal of respiratory cell and molecular biology.
[167] Ali Khademhosseini,et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[168] V. H. Lee,et al. Monolayers of Human Alveolar Epithelial Cells in Primary Culture for Pulmonary Absorption and Transport Studies , 1999, Pharmaceutical Research.
[169] C. Ehrhardt,et al. In vitro cell culture models for the assessment of pulmonary drug disposition , 2008 .
[170] M. Gaca,et al. In Vitro Models of Chronic Obstructive Pulmonary Disease (COPD) , 2011 .
[171] B. Oliver,et al. TGFβ1 induces IL‐6 and inhibits IL‐8 release in human bronchial epithelial cells: The role of Smad2/3 , 2010, Journal of cellular physiology.
[172] Robert Landsiedel,et al. Applicability of rat precision-cut lung slices in evaluating nanomaterial cytotoxicity, apoptosis, oxidative stress, and inflammation. , 2014, Toxicology and applied pharmacology.
[173] A. Dannenberg. Perspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines , 2010, Clinical Microbiology Reviews.
[174] T. Srichana,et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages , 2012, Drug delivery.
[175] E. Weibel,et al. Functional design of the human lung for gas exchange , 2008 .